Conditions: Hepatitis C
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 218
Healthy volunteers: no

Brief summary:
Patients with chronic hepatitis genotype 1b, who are intolerant or ineligible to Interferon alfa therapy with or without Ribavirin, will be treated for 24 weeks with Daclatasvir (DCV) Dual regimen (= Daclatasvir + Asunaprevir) and followed for an additional 24 weeks post-treatment in order to determine the safety and efficacy of the DCV DUAL regimen

Detailed description:

Arms:
arm 1: Asunaprevir 100mg soft capsule by mouth twice daily for 24 weeks and

Daclatasvir 60mg tablet by mouth once daily for 24 weeks

Interventions: intervention 1: Asunaprevir intervention 2: Daclatasvir
Intervention descriptions: intervention 1: None intervention 2: None

Protocol document: